Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets

COLUMBUS, Ohio, Nov. 10 /PRNewswire/ -- Roxane Laboratories, Inc. announced
today the approval of its Abbreviated New Drug Application (ANDA) for
Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the U.S. Food and Drug
Administration. The product is available in bottles of 100 for immediate
shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Perindopril Erbumine Tablets are AB rated to ACEON®
(perindopril erbumine) tablets. Annual sales of ACEON® are approximately $24.1
Million(1).

Full prescribing information for Perindopril Erbumine Tablets is available on
the Roxane Laboratories website at www.Roxane.com or upon request by calling
Roxane Laboratories Technical Product Information at
1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot
manufacturing and laboratory facility. The facility spans 70 acres and
currently employs over 1,000 people. Currently, Roxane Laboratories markets
over 80 medications in nearly 250 package sizes, focusing on an expanding line
of Multisource pharmaceutical products including: bulk and unit-dose liquids
and solids; coated, sustained-release and controlled- release tablets; nasal
sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim
Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim
group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US
headquarters to seven subsidiaries and a member of the Boehringer Ingelheim
group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 138
affiliates in 47 countries and approximately 41,300 employees. Since it was
founded in 1885, the family-owned company has been committed to researching,
developing, manufacturing and marketing novel products of high therapeutic
value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion
euro) while spending approximately one-fifth of net sales in its largest
business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit
http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 9/2009

ACEON® is a registered trademark of Solvay Pharmaceuticals, Inc.

SOURCE Roxane Laboratories, Inc.

Angela Chirico of Roxane Laboratories, +1-614-241-4774,
Angela.Chirico@boehringer-ingelheim.com